Teplizumab curbs beta-cell death in new-onset type 1 diabetes

02/26/2013 | PhysiciansBriefing.com

Patients with new-onset type 1 diabetes had higher rates of beta-cell death compared with those who had long-standing diabetes and those without diabetes, a study found. However, teplizumab treatment was associated with lower beta-cell death and better beta-cell function in patients with new-onset diabetes, researchers wrote in the journal Diabetes.

View Full Article in:

PhysiciansBriefing.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Sr. Compliance Director Ethics and Compliance
Medtronic
Fridley, MN
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC